News | November 01, 2024
Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Phase 3 study results will form the basis for future discussions with global regulatory authorities
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
The pooled prevalence of GERD in the Indian population is 15.6 %
The academy has secured partnerships with 15 esteemed hospitals
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Subscribe To Our Newsletter & Stay Updated
